Laurus Labs Limited vs SENORES PHARMACEUTICALS L

A side-by-side comparison of Laurus Labs Limited (LAURUSLABS) and SENORES PHARMACEUTICALS L (SENORES) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, SENORES PHARMACEUTICALS L leads LAURUSLABS vs SENORES on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation13
  • Profitability22
  • Growth02
  • Size & financial health31
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

SENORES takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

125.08
P/E ratio
51.55
19.74
P/B ratio
7.21
0.10%
Dividend yield
0.00%
₹16.47
EPS
₹25.05

Profitability

Even

How efficiently each company turns capital and sales into profit. Higher is better.

16.77%
Return on equity
0.00%
17.58%
Return on capital
14.43%
26.09%
EBITDA margin
26.61%
13.07%
Net margin
19.21%

Growth

SENORES takes 2/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

4.09%
Revenue CAGR (3Y)
162.44%
3.91%
Profit CAGR (3Y)
147.66%

Size & financial health

LAURUSLABS takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.11L Cr
Market cap
₹6,072 Cr
₹6,813 Cr
Revenue
₹633 Cr
₹890 Cr
Net profit
₹122 Cr
0.45
Debt / equity
0.37
Laurus Labs Limited
  • + []
  • − ["Stock is trading at 21.00 times its book value", "The company has delivered a poor sales growth of 7.2% over past five years.", "The company has delivered a poor profit growth of -2.0% over past five years."]
SENORES PHARMACEUTICALS L
  • + ["Company has delivered good profit growth of 161.2% CAGR over last 5 years", "Company has delivered good sales growth of 139.7% CAGR over last 5 years"]
  • − ["Stock is trading at 6.50 times its book value", "Though the company is reporting repeated profits, it is not paying out dividend"]
Laurus Labs Limited full analysis SENORES PHARMACEUTICALS L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.